Myelosuppression and Tuberculosis

13th webinar of the Virtual Medical Consilium (VMC), from February 11, 2022.

The webinar agenda includes:

- Welcoming remarks. Dr Askar Yedilbayev, Team Lead (TB), Joint Infectious Diseases Unit, Division of Country Health Programmes, WHO Regional Office for Europe, Copenhagen, Denmark.

- Preliminary analysis of Serious Adverse Events related to myelosuppression within mSTR operational research. Mr Oleksandr Korotych, Technical Officer, TB Team, Joint Infectious Diseases Unit, Division of Country Health Programmes, WHO Regional Office for Europe, Copenhagen, Denmark.

- Myelosuppression related to new TB drugs and its management. Dr Nino Lomtadze, VMC expert, Georgia.

- Experience of Tajikistan in management of MDR/RR-TB patient with myelosuppression within mSTR operational research. Dr Firuza Saidova, NTP, Tajikistan.

1. Is there any role for injectable_ENG (1).pdf 1. Is there any role for injectable_RUS (1).pdf 2. Management of MDR_RR-TB Patients With Renal Failure_ENG (1).pdf 2. Ведение МЛУ_РУ-ТБ пациентов_RUS (1).pdf 3. Clinical case_ENG (1).pdf 3. Клинический случай_RUS (1).pdf